GLP-1 ameliorates the proliferation activity of INS-1 cells inhibited by intermittent high glucose concentrations through the regulation of cyclins

Zhang,Zhen; Li,Jing; Jiang,Xinkui; Yang,Lei; Lei,Lei; Cai,Dehong; Zhang,Hua; Chen,Hong

doi:10.3892/mmr.2014.2265

GLP-1 ameliorates the proliferation activity of INS-1 cells inhibited by intermittent high glucose concentrations through the regulation of cyclins

Authors:
- Zhen Zhang
- Jing Li
- Xinkui Jiang
- Lei Yang
- Lei Lei
- Dehong Cai
- Hua Zhang
- Hong Chen
View Affiliations

Affiliations: Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China, Department of Endocrinology, Nanshan Affiliated Hospital of Guangdong Medical College, Shenzhen, Guangdong, P.R. China, Function Department of Nanshan Maternal and Child's Hospital, Shenzhen, Guangdong, P.R. China, Department of Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China
Published online on: May 22, 2014 https://doi.org/10.3892/mmr.2014.2265
Pages: 683-688

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glucagon-like peptide-1 (GLP-1) and its analog exendin (EX)-4 have been considered to promote β-cell growth and expansion. In the present, study we investigated the effect of GLP-1 on proliferative activity and cell cycle regulation in the pancreatic insulin-secreting β-cell line, INS-1, treated with intermittent high glucose. INS-1 cells were treated with normal glucose (5.5 mmol/l), constant high glucose (30 mmol/l) and intermittent high glucose (rotation/24 h in 5.5 or 30 mmol/l) in the presence or absence of GLP-1 (100 nmol/l) for seven days. Proliferative activity, cell cycle and the expression of cyclin D1, p21, p27 and Skp2 were examined. INS-1 treated with intermittent high glucose and GLP-1 demonstrated a significant increase in proliferation activity (1.45±0.12; P<0.01) and decreased cell proportion in G0/G1 phase (49.73±4.04%, P<0.01) compared with those without GLP-1. Furthermore, the expression levels of cyclin D1 and Skp2 were increased, while the expression of p27 and p21 were significantly reduced. Similar results were identified in those treated with constant high glucose and GLP-1. These results suggest that GLP-1 may ease the G0/G1 cell cycle arrest of INS-1 cells induced by intermittent high glucose by upregulating the expression of cyclin D1 and Skp2, downregulating the expression of p21 and p27, and finally promoting the cell cycle progression and proliferation activity.

View Figures

View References

1	Prentki M and Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest. 116:1802–1812. 2006. View Article : Google Scholar : PubMed/NCBI
2	Rhodes CJ: Type 2 diabetes-a matter of beta-cell life and death? Science. 307:380–384. 2005. View Article : Google Scholar : PubMed/NCBI
3	Azuma K, Kawamori R, Toyofuku Y, Kitahara Y, Sato F, Shimizu T, Miura K, Mine T, Tanaka Y, Mitsumata M and Watada H: Repetitive fluctuations in blood glucose enhances monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler Thromb Vasc Biol. 26:2275–2280. 2006. View Article : Google Scholar : PubMed/NCBI
4	Sun LQ, Chen YY, Wang X, Li XJ, Xue B, Qu L, Zhang TT, Mu YM and Lu JM: The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol. 84:961–973. 2012. View Article : Google Scholar : PubMed/NCBI
5	Kohnert KD, Freyse EJ and Salzsieder E: Glycaemic variability and pancreatic β-cell dysfunction. Curr Diabetes Rev. 8:345–354. 2012.
6	Holz GG and Chepurny OG: Diabetes outfoxed by GLP-1? Sci STKE. 268:pe22005.PubMed/NCBI
7	Tschen SI, Dhawan S, Gurlo T and Bhushan A: Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes. 58:1312–1320. 2009. View Article : Google Scholar : PubMed/NCBI
8	Baggio LL and Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 132:2131–2157. 2007. View Article : Google Scholar : PubMed/NCBI
9	Okada T, Liew CW, Hu J, Hinault C, Michael MD, Krtzfeldt J, Yin C, Holzenberger M, Stoffel M and Kulkarni RN: Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci USA. 104:8977–8982. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kim MJ, Kang JH, Park YG, Ryu GR, Ko SH, Jeong IK, Koh KH, Rhie DJ, Yoon SH, Hahn SJ, Kim MS and Jo YH: Exendin-4 induction of cyclin D1 expression in INS-1 beta-cells: involvement of cAMP-responsive element. J Endocrinol. 188:623–633. 2006. View Article : Google Scholar : PubMed/NCBI
11	Song WJ, Schreiber WE, Zhong E, Liu FF, Kornfeld BD, Wondisford FE and Hussain MA: Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes. 57:2371–2381. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zhan Y, Sun HL, Chen H, Zhang H, Sun J, Zhang Z and Cai DH: Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis. Med Sci Monit. 18:BR286–BR291. 2012. View Article : Google Scholar : PubMed/NCBI
13	Mwitari PG, Ayeka PA, Ondicho J, Matu EN and Bii CC: Antimicrobial activity and probable mechanisms of action of medicinal plants of Kenya: Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus. PloS One. 8:e656192013. View Article : Google Scholar
14	Zhang T, Tan Y, Zhao R and Liu Z: DNA damage induced by oridonin involves cell cycle arrest at G2/M phase in human MCF-7 cells. Contemp Oncol (Pozn). 17:38–44. 2013.PubMed/NCBI
15	Tschen SI, Dhawan S, Gurlo T and Bhushan A: Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes. 58:1312–1320. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kim W and Egan JM: The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 60:470–512. 2008. View Article : Google Scholar : PubMed/NCBI
17	Drucker DJ: Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endoerinol. 17:161–171. 2003. View Article : Google Scholar : PubMed/NCBI
18	Portha B, Tourrel-Cuzin C and Movassat J: Activation of the GLP-1 receptor signaling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res. 2011:3765092011. View Article : Google Scholar : PubMed/NCBI
19	Drucker DJ: Incretin-based therapy and the quest for sustained improvements in β-cell health. Diabetes Care. 34:2133–2135. 2011.PubMed/NCBI
20	Feanny MA, Fagan SP, Ballian N, Liu SH, Li Z, Wang X, Fisher W, Brunicardi FC and Belaguli NS: PDX-1 expression is associated with islet proliferation in vitro and in vivo. J Surg Res. 144:8–16. 2008. View Article : Google Scholar : PubMed/NCBI
21	Bicknell KA, Surry EL and Brooks G: Targeting the cell cycle machinery for the treatment of cardiovascular disease. J Pharm Pharmacol. l55:571–591. 2003. View Article : Google Scholar : PubMed/NCBI
22	Pines J: Cyclin-dependent kinase inhibitors: the age of crystals. Biochim Biophys Acta. 1332:M39–M42. 1997.PubMed/NCBI
23	Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 3:222–225. 1997. View Article : Google Scholar : PubMed/NCBI
24	Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1:193–199. 1999. View Article : Google Scholar : PubMed/NCBI
25	Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M and Hershko A: Role of the SCFSkp2 ubiquitin ligase in the degradation ofp21Cip1 in S phase. J Biol Chem. 278:25752–25757. 2003. View Article : Google Scholar : PubMed/NCBI
26	Frödin M, Sekine N, Roche E, Filloux C, Prentki M, Wollheim CB and Van Obberghen E: Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting β-cell line, INS-1. J Biol Chem. 270:7882–7889. 1995.PubMed/NCBI
27	List JF and Habener JF: Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells. Am J Physiol Endocrinol Metab. 286:E875–E881. 2004.
28	Susini S, Roche E, Prentki M and Schlegel W: Glucose and glucoincretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. FASEB J. 12:1173–1182. 1998.PubMed/NCBI
29	Kang JH, Kim MJ, Ko SH, Jeong IK, Koh KH, Rhie DJ, Yoon SH, Hahn SJ, Kim MS and Jo YH: Upregulation of rat Ccnd1 gene by exendin-4 in pancreatic beta cell line INS-1: interaction of early growth response-1 with cis-regulatory element. Diabetologia. 49:969–979. 2006. View Article : Google Scholar : PubMed/NCBI
30	Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, Petersen JS, Nielsen JH and Møldrup A: Stimulation of pancreatic-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. Endocrinol. 188:481–492. 2006. View Article : Google Scholar : PubMed/NCBI
31	Kossatz U, Dietrich N, Zender L, Buer J, Manns MP and Malek NP: Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18:2602–2607. 2004. View Article : Google Scholar : PubMed/NCBI
32	Frouin I, Montecucco A, Biamonti G, Hübscher U, Spadari S and Maga G: Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. EMBO J. 21:2485–2495. 2002. View Article : Google Scholar : PubMed/NCBI
33	Tschen SI, Georgia S, Dhawan S and Bhushan A: Skp2 is required for incretin hormone-mediated β-cell proliferation. Mol Endocrinol. 25:2134–43. 2011.PubMed/NCBI
34	Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI